Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ELI LILLY & Co | Financial_Report.xls |
| 10-K - FORM 10-K - ELI LILLY & Co | c55339ke10vk.htm |
| EX-32 - EX-32 - ELI LILLY & Co | c55339kexv32.htm |
| EX-23 - EX-23 - ELI LILLY & Co | c55339kexv23.htm |
| EX-21 - EX-21 - ELI LILLY & Co | c55339kexv21.htm |
| EX-31.2 - EX-31.2 - ELI LILLY & Co | c55339kexv31w2.htm |
| EX-10.4 - EX-10.4 - ELI LILLY & Co | c55339kexv10w4.htm |
| EX-31.1 - EX-31.1 - ELI LILLY & Co | c55339kexv31w1.htm |
| EX-10.3 - EX-10.3 - ELI LILLY & Co | c55339kexv10w3.htm |
| EX-10.5 - EX-10.5 - ELI LILLY & Co | c55339kexv10w5.htm |
| EX-10.12 - EX-10.12 - ELI LILLY & Co | c55339kexv10w12.htm |
| EX-10.8 - EX-10.8 - ELI LILLY & Co | c55339kexv10w8.htm |
EXHIBIT 12. STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS (LOSS) TO FIXED CHARGES
Eli Lilly and Company and Subsidiaries
(Dollars in millions)
(Dollars in millions)
| Years Ended December 31, | ||||||||||||||||||||
| 2009 | 2008 | 2007 | 2006 | 2005 | ||||||||||||||||
Consolidated pretax income (loss)
before cumulative effect of a
change in accounting principle |
$ | 5,357.8 | $ | (1,307.6 | ) | $ | 3,876.8 | $ | 3,418.0 | $ | 2,717.5 | |||||||||
Interest1 |
291.5 | 276.5 | 322.5 | 344.8 | 245.7 | |||||||||||||||
Less interest capitalized
during the period |
(30.2 | ) | (48.2 | ) | (94.2 | ) | (106.7 | ) | (140.5 | ) | ||||||||||
Earnings (Loss) |
$ | 5,619.1 | $ | (1,079.3 | ) | $ | 4,105.1 | $ | 3,656.1 | $ | 2,822.7 | |||||||||
Fixed charges |
$ | 291.5 | $ | 276.5 | $ | 322.5 | $ | 344.8 | $ | 245.7 | ||||||||||
Ratio of earnings to
fixed charges |
19.3 | N/M | 2 | 12.7 | 10.6 | 11.5 | ||||||||||||||
| N/M — Not Meaningful | ||
| 1 | Interest is based upon interest expense reported as such in the consolidated income statement and does not include any interest related to unrecognized tax benefits, which is included in income tax expense. | |
| 2 | For such ratio, earnings were $1,307.6 million less than fixed charges. The loss for the year ended December 31, 2008 included special charges related to the EDPA settlement of $1,477.0 million and acquired in-process research and development expense of $4,685.4 million associated with the ImClone acquisition, as described in greater detail in the notes to the accompanying consolidated financial statements. | |